Developments in Smoking Cessation Interventions for Patients with Chronic Obstructive Pulmonary Disease in the Past 5 Years: a Scoping Review

Feng Lin,Xiaoshuang Lv,Yingquan Wang,Shuilian Chu,Zeqi Dai,Hang Jing,Zhaohui Tong,Xing Liao,Lirong Liang
DOI: https://doi.org/10.1080/17476348.2022.2108797
2022-01-01
Expert Review of Respiratory Medicine
Abstract:Smoking cessation is the most effective strategy for slowing the progression of chronic obstructive pulmonary disease (COPD). However, COPD patients find it difficult to quit smoking with standard cessation interventions. A scoping review of smoking cessation for COPD patients was conducted by searching the MEDLINE, Embase, and Cochrane Library databases for all studies published between 1 January 2016 and 22 September 2021. Four themes were set up and 47 studies were included eventually. The majority of the included studies (61.7%, 29/47) investigated efficacy and effectiveness, including new strategies for extended treatment and mobile health (mHealth) delivery approach. Studies examining accessibility and utilization (31.9%, 15/47), safety (10.6%, 5/47), and health economics (6.4%, 3/47) were also reviewed. The quality of the included randomized controlled trials was also evaluated. Pharmacotherapy combined with behavioral interventions delivered via mHealth may be a promising strategy to help COPD smokers quit. However, the overall quality of the current studies is poor, making it challenging for clinicians to make informed decisions. Future high-quality studies are needed to provide conclusive evidence on the optimal pharmacotherapies and the most cost-effective comprehensive smoking cessation interventions, particularly those integrated into disease management for smokers with COPD.
What problem does this paper attempt to address?